http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101004205-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate | 2008-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101004205-B1 |
| titleOfInvention | Controlled Release Compositions for Preparing Udenafil-Containing Sustained-Release Formulations |
| abstract | FIELD OF THE INVENTION The present invention relates to controlled release compositions for the preparation of sustained release formulations containing udenafil, specifically (A) udenafil and pharmaceutically acceptable salts, (B) solubility modifiers, (C) adsorbents And (D) a controlled release composition for producing a udenafil-containing sustained release formulation comprising a hydrophilic polymer.n n n Controlled-release composition for preparing a udenafil-containing sustained-release preparation according to the present invention can release the drug constantly regardless of the pH in the stomach and intestine to freely control the release time of the drug between 3 to 24 hours, between individuals Sustained-release preparations that not only reduce the deviation of drug efficacy but also have optimal conditions for the treatment of diseases requiring long-term drug use such as pulmonary hypertension, portal vein hypertension, and prostatic hypertrophy treated by udenafil. It can be prepared, and can be usefully used in the prevention and treatment of erectile dysfunction by controlling the release according to the appropriate absorption time when applied to a living body.n n n n Eudenafil, controlled release |
| priorityDate | 2008-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.